Career Henan Chemical Co.450051About UsRoom 702, Floor 7, Building 10, National University Science Park, High-Tech Zone, Zhengzhou City, Henan Province, ChinaCareer Henan Chemical Co.founded in 2014, it has a highly experienced research team. The company is committed to drug R&D services. Our mission is to deliver high quality and speedy chemistry services through the continuous improvement in research capability and efficiency. Our focus on technology innovation and process optimization allows us to fulfill research needs customers. With excellent product quality and strong research and development capabilities, the company has established deep cooperative relations with a number of well-known universities and research institutes, and
Career Henan Chemical Co.founded in 2014, it has a highly experienced research team. The company is committed to drug R&D services. Our mission is to deliver high quality and speedy chemistry services through the continuous improvement in research capability and efficiency. Our focus on technology innovation and process optimization allows us to fulfill research needs customers. With excellent product quality and strong research and development capabilities, the company has established deep cooperative relations with a number of well-known universities and research institutes, and established long-term and stable strategic cooperative relations with a number of well-known pharmaceutical enterprises around the world. We are committed to supporting our clients in their new drug research and development in the best possible way. Reach the clients’ target; Achieve clients’ satisfaction; Exceed client’s expectations. Use our heart to communicate with our clients and serve our clients with the highest integrity.
1-Adamantane Carboxaldehyde In recent years, the biological activities and synthesis methods of amantadine derivatives have been further studied. SAXAGLIPTIN is a highly effect
1, 8-Bis (Dimethylamino)Naphthalene On November 15, 2010, the FDA approved Halaven for the treatment of patients with metastatic breast cancer who have received at least two